One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer
doi : 10.1016/j.annonc.2023.12.010
Volume 35, Issue 2, February 2024, Pages 147-149
Unlocking precision oncology with FGFR inhibition in urothelial carcinoma
doi : 10.1016/j.annonc.2023.11.006
Volume 35, Issue 2, February 2024, Pages 150-153
Challenges of artificial intelligence in precision oncology: public-private partnerships including national health agencies as an asset to make it happen
doi : 10.1016/j.annonc.2023.09.3106
Volume 35, Issue 2, February 2024, Pages 154-158
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
doi : 10.1016/j.annonc.2023.11.016
Volume 35, Issue 2, February 2024, Pages 159-182
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
doi : 10.1016/j.annonc.2023.11.008
Volume 35, Issue 2, February 2024, Pages 183-189
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
doi : 10.1016/j.annonc.2023.09.3108
Volume 35, Issue 2, February 2024, Pages 190-199
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
A. Necchi 1, D. Pouessel 2 , R. Leibowitz 3,4 , S. Gupta 5 , A. Fléchon6 , J. GarcÃa-Donas 7 , M. A. Bilen8 , P. R. Debruyne 9,10,11 , M. I. Milowsky12 , T. Friedlander 13 , M. Maio 14 , A. Gilmartin 15 , X. Li 15 , M. L. Veronese 16 & Y. Loriot
doi : 10.1016/j.annonc.2023.10.794
Volume 35, Issue 2, February 2024, Pages 200-210
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma☆
B. Lian 1y, Z. Li 2y, N. Wu 3 , M. Li4 , X. Chen 5 , H. Zheng6 , M. Gao 6 , D. Wang 7 , X. Sheng1 , H. Tian 1 , L. Si1 , Z. Chi 1 , X. Wang 1 , Y. Lai 2 , T. Sun8 , Q. Zhang8 , Y. Kong 1 , G. V. Long 9 , J. Guo 1 & C. Cui1
doi : 10.1016/j.annonc.2023.10.793
Volume 35, Issue 2, February 2024, Pages 211-220
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
K. D. Lewis1y, K. Peris 2,3 , A. Sekulic4 , A. J. Stratigos 5 , L. Dunn6 , Z. Eroglu 7 , A. L. S. Chang 8 , M. R. Migden9,10 , S.-Y. Yoo 11 , K. Mohan 11 , E. Coates 11 , E. Okoye11 , T. Bowler 11z, J.-F. Baurain12 , O. Bechter13 , A. Hauschild 14 , M. O. Butler15 , L. Hernandez-Aya 16x, L. Licitra 17,18 , R. I. Neves 19{, E. S. Ruiz 20 , F. Seebach 11 , I. Lowy 11 , P. Goncalves 11 & M. G. Fury
doi : 10.1016/j.annonc.2023.10.123
Volume 35, Issue 2, February 2024, Pages 221-228
Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer—evaluation in a nationwide Danish cohort
T. V. Henriksen 1,2 , C. Demuth 1,2 , A. Frydendahl 1,2 , J. Nors1,2 , M. Nesic1,2 , M. H. Rasmussen 1,2 , T. Reinert 1,2 , O. H. Larsen1,2 , C. Jaensch 3 , U. S. Løve4 , P. V. Andersen 5 , T. Kolbro6 , O. Thorlacius-Ussing 7 , A. Monti 8 , M. Gögenur 9 , J. Kildsig 10 , P. Bondeven 11 , N. H. Schlesinger12 , L. H. Iversen13 , K. A. Gotschalck 14 & C. L. Andersen
doi : 10.1016/j.annonc.2023.11.009
Volume 35, Issue 2, February 2024, Pages 229-239
Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer
doi : 10.1016/j.annonc.2023.10.120
Volume 35, Issue 2, February 2024, Pages 240-241
Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline
doi : 10.1016/j.annonc.2023.10.129
Volume 35, Issue 2, February 2024, Pages 241-243
